Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.verified

SYRE

Price:

$33.51

Market Cap:

$2.02B

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; S...[Read more]

Industry

Biotechnology

IPO Date

2016-04-07

Stock Exchange

NASDAQ

Ticker

SYRE

The Enterprise Value as of December 2025 (TTM) for Spyre Therapeutics, Inc. (SYRE) is 1.96B

According to Spyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.96B. This represents a change of -7.71% compared to the average of 2.12B of the last 4 quarters.

Spyre Therapeutics, Inc. (SYRE) Historical Enterprise Value (quarterly & annually)

How has SYRE Enterprise Value performed in the past?

The mean historical Enterprise Value of Spyre Therapeutics, Inc. over the last ten years is 220.45M. The current 1.96B Enterprise Value has changed 88.77% with respect to the historical average. Over the past ten years (40 quarters), SYRE's Enterprise Value was at its highest in in the September 2025 quarter at 5.73B. The Enterprise Value was at its lowest in in the June 2023 quarter at -187908015.60.

Quarterly (TTM)
Annual

Average

220.45M

Median

107.94M

Minimum

-5153996.25

Maximum

1.01B

Spyre Therapeutics, Inc. (SYRE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Spyre Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 2.18%

Maximum Annual Enterprise Value = 1.01B

Minimum Annual Increase = -1439.28%

Minimum Annual Enterprise Value = -5153996.25

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20241.01B2.18%
202344.09M473.13%
20227.69M-97.45%
2021302.20M-9.89%
2020335.39M45.84%
2019229.96M72.26%
2018133.50M93.40%
201769.03M-1439.28%
2016-5153996.25-106.26%
201582.38M-37.14%

Spyre Therapeutics, Inc. (SYRE) Average Enterprise Value

How has SYRE Enterprise Value performed in the past?

The current Enterprise Value of Spyre Therapeutics, Inc. (SYRE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

352.39M

5-year avg

338.95M

10-year avg

220.45M

Spyre Therapeutics, Inc. (SYRE) Enterprise Value vs. Peers

How is SYRE’s Enterprise Value compared to its peers?

Spyre Therapeutics, Inc.’s Enterprise Value is greater than Pharvaris N.V. (1.34B), greater than Immunome, Inc. (1.70B), greater than Wave Life Sciences Ltd. (1.07B), greater than Intellia Therapeutics, Inc. (925.20M), greater than Zymeworks Inc. (-43935349065.00), greater than Maze Therapeutics, Inc. (1.76B), greater than AbCellera Biologics Inc. (1.15B), greater than Upstream Bio, Inc. (1.46B), greater than Ardelyx, Inc. (1.58B), greater than Celldex Therapeutics, Inc. (1.95B),

Build a custom stock screener for Spyre Therapeutics, Inc. (SYRE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Spyre Therapeutics, Inc. (SYRE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Spyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Spyre Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Spyre Therapeutics, Inc. (SYRE)?

What is the 3-year average Enterprise Value for Spyre Therapeutics, Inc. (SYRE)?

What is the 5-year average Enterprise Value for Spyre Therapeutics, Inc. (SYRE)?

How does the current Enterprise Value for Spyre Therapeutics, Inc. (SYRE) compare to its historical average?